Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 3/20 | 0.42 |
| ▸ | FABP3 | P05413 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199950 | 0.85 | ALDH1A1 (0.48) | GABRA1GABRB2FABP4FABP3GAA | |
| SCHEMBL9064395 | 0.83 | GABRA1 (0.52) | GABRA1GABRB2FABP4FABP3GAA | |
| SCHEMBL27889312 | 0.79 | GABRA1 (0.45) | GABRA1GABRB2FABP4FABP3GAA | |
| SCHEMBL26521897 | 0.76 | GABRA1 (0.63) | GABRA1GABRB2FABP4FABP3GAA | |
| SCHEMBL3440745 | 0.75 | GABRA1 (0.50) | GABRA1GABRB2FABP4FABP3GAA | |
| SCHEMBL8976031 | 0.74 | GAA (0.38) | GAAALDH1A1ALOX12HTTHIF1A | |
| SCHEMBL840954 | 0.74 | DHFR (0.41) | GAAALDH1A1POLBGFER | |
| SCHEMBL27439431 | 0.73 | GABRA1 (0.65) | GABRA1GABRB2FABP4FABP3GAA | |
| SCHEMBL18380019 | 0.73 | GABRA1 (0.48) | GABRA1GABRB2FABP4FABP3FABP5 | |
| SCHEMBL10334357 | 0.72 | GAA (0.42) | GABRA1GABRB2FABP4FABP3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10960036-B2 | Pharmaceutical composition for preventing and treating alpha herpes virus infection, containing, as active ingredient, Elaeocarpus sylvestris extract or fraction thereof | GENENCELL CO., LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960036-B2 | Pharmaceutical composition for preventing and treating alpha herpes virus infection, containing, as active ingredient, Elaeocarpus sylvestris extract or fraction thereof | ACHE, EPHA3, EPHA1 | GABRA1 2466/4885GABRB2 2920/4885FABP4 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.